Form D · Biotechnology

Tinos Therapeutics, Inc.

Cambridge, MA · CIK 0002088485

Offering snapshot reported Apr 17, 2026 · SEC filing

Reported sold
$2.25M
Offering amount: $4M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 4, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.13M$2.25MSep 26, 2025: $1,000,000.00Sep 26, 2025Apr 17, 2026: $2,250,000.00Apr 17, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,000,000 → $2,250,000
  • Reported investors1 → 3

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 17, 2026Amendment$2,250,000$1,250,000vs Sep 26, 20253SEC filing
Sep 26, 2025Initial$1,000,000No comparison1SEC filing

Offering details

Securities
Option to acquire
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-558952

Source: Form D, filed Apr 17, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Karambizi Director, Executive
Anastasios Polimenakos Director
Nikolaos Tapinos Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
700 Main Street
Cambridge, MA, 02139